We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
FERRIC CARBOXYMALTOSE-TEVA (Teva Pharma Australia Pty Ltd)
Product name
FERRIC CARBOXYMALTOSE-TEVA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
118 (255 working days)
Active ingredients
ferric carboxymaltose
Registration type
New generic medicine
Indication
FERRIC CARBOXYMALTOSE-TEVA is indicated for the treatment of iron deficiency in adults and adolescents aged 14 years and older when:
- oral iron preparations are ineffective
- oral iron preparations cannot be used
- there is a clinical need to deliver iron rapidly
- The diagnosis of iron deficiency must be based on laboratory tests.
FERRIC CARBOXYMALTOSE-TEVA is indicated for the treatment of iron deficiency anaemia in children aged 1 to 13 years when:
- oral iron preparations are ineffective
- oral iron preparations cannot be used
The diagnosis of iron deficiency anaemia must be based on laboratory tests.